IPO
The third time may be the charm for Framingham, Mass.-based Alzheon when it comes to an initial public offering – because the company has balked the first two times it attempted to go public on the stock exchange.
Despite the government shutdown, at least two biotech companies, Kaleido Biosciences and Cirius Therapeutics, have filed with the U.S. Securities and Exchange Commission (SEC) for initial public offerings (IPO).
Galapagos NV received a transparency notification from Sands Capital Management, LLC.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
Cambridge, Mass.-based TCR2 Therapeutics is looking to secure $100 million in an initial public offering. Just before the end of 2018, the company filed its prospectus with the U.S. Securities and Exchange Commission, hoping that the new year will continue the IPO frenzy biotech enjoyed for much of 2018.
Immunicum AB has, as previously announced, implemented a directed issue to a number of institutional and private investors. The newly implemented share issue has entailed a change in number of shares and votes in the Company.
Harpoon initiated a Phase I trial for its lead candidate for prostate cancer earlier this summer.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a look at some of the key Massachusetts-based IPOs.
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.
PRESS RELEASES